CRISPR and CAS Gene Market Revenue Develop Rapidly by Key Vendors | Caribou Biosciences, CRISPR Therapeutics, Mirus Bio LLC

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential for the adaptive immunity in few bacteria and archaea, enabling the organisms to respond to and to eliminate invading genetic material. These gene editing tools are extensively used in agriculture and food security.

Many food and agricultural organizations are working on receiving license for using CRISPR and CAS gene technology for creating novel products in food and agriculture business. For instance, in September 2016, agrochemical and agricultural biotechnology corporation Monsanto secured a worldwide non-exclusive license agreement for agricultural applications of CRISPR technology from the Broad Institute. CRISPR and CAS genes are also used in treating a number of diseases such as cancer, blood disorders, AIDS, and genetic disorders such as cystic fibrosis, Huntington’s etc.

Get Free Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @  https://www.coherentmarketinsights.com/insight/request-sample/2598

Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and Huntington’s disease worldwide is highly contributing to the market growth of CRISPR and CAS gene market, as many genetic disabilities can be corrected using this gene editing technology. According to National Health Service (NHS) U.K. 2018 report, the highest rate of Huntington’s disease in the United Kingdom is 12 per 100,000 people. Also, in the U.S., an estimated 10 per 100,000 have the faulty Huntington’s gene and live either waiting for symptoms to begin or live/struggle with the disease.

Government bodies are taking initiatives for developing treatment of Huntington’s disease. For instance, in 2016, US-based Company Addgene has developed the KamiCas9, a version of CRISPR-Cas9 that includes a ‘self-inactivating’ KamiCas9 system for the editing of CNS disease genes for treatment of Huntington’s disease.

However, the CRISPR and CAS gene market growth is hindered by the ethical issues, which is the major concern for every gene therapy. For instance, in April 2015, the US National Institutes of Health issued a statement indicating that it will not fund any research that uses genome editing tools such as CRISPR in human embryos due to ethical issues.

Key features of the study:

This report provides in-depth analysis of the CRISPR and CAS Gene market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2026, considering 2018, as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global CRISPR and CAS Gene market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global CRISPR and CAS Gene market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for CRISPR and CAS Gene market, research and consulting firms, new entrants, and financial analysts

Buy This Complete A Business Report:  https://www.coherentmarketinsights.com/insight/buy-now/2598 

Company Profiles:

Caribou Biosciences Inc.*
CRISPR Therapeutics
Mirus Bio LLC
Editas Medicine
Takara Bio Inc.
Synthego Corporation
Thermo Fisher Scientific, Inc.
GenScript
Addgene
Merck KGaA (Sigma-Aldrich)
Integrated DNA Technologies, Inc.
Transposagen Biopharmaceuticals, Inc.
OriGene Technologies, Inc.
New England Biolabs
Dharmacon, Cellecta, Inc.
Agilent Technologies
Applied StemCell, Inc.

Detailed Segmentation:

By Product Type:
Vector-based Cas
DNA-free Cas

By Application:
Genome Engineering
Disease models
Functional Genomics
Knockdown/activation
Other Applications

By End User:
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.